

# Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk

Minta Thomas,<sup>1</sup> Lori C. Sakoda,<sup>1,2</sup> Michael Hoffmeister,<sup>3</sup> Elisabeth A. Rosenthal,<sup>4</sup> Jeffrey K. Lee,<sup>2</sup> Franzel J.B. van Duijnhoven,<sup>5</sup> Elizabeth A. Platz,<sup>6</sup> Anna H. Wu,<sup>7</sup> Christopher H. Dampier,<sup>8</sup> Albert de la Chapelle,<sup>9</sup> Alicja Wolk,<sup>10</sup> Amit D. Joshi,<sup>11,12</sup> Andrea Burnett-Hartman,<sup>13</sup> Andrea Gsur,<sup>14</sup> Annika Lindblom,<sup>15,16</sup> Antoni Castells,<sup>17</sup> Aung Ko Win,<sup>18</sup> Bahram Namjou,<sup>19,20,21</sup> Bethany Van Guelpen,<sup>22,23</sup> Catherine M. Tangen,<sup>24</sup> Qianchuan He,<sup>1</sup> Christopher I. Li,<sup>1</sup> Clemens Schafmayer,<sup>25</sup> Corinne E. Joshi,<sup>6</sup> Cornelia M. Ulrich,<sup>26</sup> D. Timothy Bishop,<sup>27</sup> Daniel D. Buchanan,<sup>28,29,30</sup> Daniel Schaid,<sup>31</sup> David A. Drew,<sup>11</sup> David C. Muller,<sup>32</sup> David Duggan,<sup>33</sup> David R. Crosslin,<sup>34</sup> Demetrius Albanes,<sup>35</sup> Edward L. Giovannucci,<sup>12,36,37</sup> Eric Larson,<sup>38</sup> Flora Qu,<sup>1</sup> Frank Mentch,<sup>39</sup> Graham G. Giles,<sup>18,40,41</sup> Hakon Hakonarson,<sup>39</sup> Heather Hampel,<sup>42</sup> Ian B. Stanaway,<sup>4</sup> Jane C. Figueiredo,<sup>43,44</sup> Jeroen R. Huyghe,<sup>1</sup> Jessica Minnier,<sup>45</sup> Jenny Chang-Claude,<sup>46,47</sup> Jochen Hampe,<sup>48</sup> John B. Harley,<sup>19,20,21</sup> Kala Visvanathan,<sup>6</sup> Keith R. Curtis,<sup>1</sup> Kenneth Offit,<sup>49,50</sup> Li Li,<sup>51</sup> Loic Le Marchand,<sup>52</sup> Ludmila Vodickova,<sup>53,54,55</sup> Marc J. Gunter,<sup>56</sup> Mark A. Jenkins,<sup>18</sup> Martha L. Slattery,<sup>57</sup> Mathieu Lemire,<sup>58</sup> Michael O. Woods,<sup>59</sup> Mingyang Song,<sup>11,60,61,62</sup> Neil Murphy,<sup>56</sup> Noralane M. Lindor,<sup>64</sup> Ozan Dikilitas,<sup>65</sup> Paul D.P. Pharoah,<sup>66</sup> Peter T. Campbell,<sup>67</sup>

(Author list continued on next page)

## Summary

Accurate colorectal cancer (CRC) risk prediction models are critical for identifying individuals at low and high risk of developing CRC, as they can then be offered targeted screening and interventions to address their risks of developing disease (if they are in a high-risk group) and avoid unnecessary screening and interventions (if they are in a low-risk group). As it is likely that thousands of genetic variants contribute to CRC risk, it is clinically important to investigate whether these genetic variants can be used jointly for CRC risk prediction. In this paper, we derived and compared different approaches to generating predictive polygenic risk scores (PRS) from genome-wide association studies (GWASs) including 55,105 CRC-affected case subjects and 65,079 control subjects of European ancestry. We built the PRS in three ways, using (1) 140 previously identified and validated CRC loci; (2) SNP selection based on linkage disequilibrium (LD) clumping followed by machine-learning approaches; and (3) LDpred, a Bayesian approach for genome-wide risk prediction. We tested the PRS in an independent cohort of 101,987 individuals with 1,699 CRC-affected case subjects. The discriminatory accuracy, calculated by the age- and sex-adjusted area under the receiver operating characteristics curve (AUC), was highest for the LDpred-derived PRS (AUC = 0.654) including nearly 1.2 M genetic variants (the proportion of causal genetic variants for CRC assumed to be 0.003), whereas the PRS of the 140 known variants identified from GWASs had the lowest AUC (AUC = 0.629). Based on the LDpred-derived PRS, we are able to identify 30% of individuals without a family history as having risk for CRC similar to those with a family history of CRC, whereas the PRS based on known GWAS variants identified only top 10% as having a similar relative risk. About 90% of these individuals have no family history and would have been considered average risk under current screening guidelines, but might benefit from earlier screening. The developed PRS offers a way for risk-stratified CRC screening and other targeted interventions.

## Introduction

Colorectal cancer (CRC) is a leading cause of cancer death, yet it is among the most preventable cancers in part

because CRC screening is effective for both early detection of treatable cancers and for reducing cancer risk by removing pre-cancerous lesions.<sup>1</sup> Despite improvements in screening and treatment, about 50,000 fatal CRC cases

<sup>1</sup>Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; <sup>2</sup>Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA; <sup>3</sup>Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany; <sup>4</sup>Department of Medicine (Medical Genetics), University of Washington Medical Center, Seattle, WA 98195, USA; <sup>5</sup>Division of Human Nutrition and Health, Wageningen University & Research, Wageningen 176700, the Netherlands; <sup>6</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA; <sup>7</sup>University of Southern California, Preventative Medicine, Los Angeles, CA 90089, USA; <sup>8</sup>Department of Surgery, University of Virginia Health System, Charlottesville, VA 22903, USA; <sup>9</sup>Department of Cancer Biology and Genetics and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; <sup>10</sup>Institute of Environmental Medicine, Karolinska Institutet, Stockholm 17177, Sweden; <sup>11</sup>Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; <sup>12</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; <sup>13</sup>Institute for Health Research, Kaiser Permanente Colorado, Denver, CO 80014, USA; <sup>14</sup>Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna 1090, Austria; <sup>15</sup>Department of Clinical Genetics, Karolinska University Hospital, Stockholm 17177, Sweden; <sup>16</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm 17177, Sweden; <sup>17</sup>Gastroenterology Department, Hospital Clinic, Institut

(Affiliations continued on next page)



Polly A. Newcomb,<sup>1,68</sup> Roger L. Milne,<sup>18,40,41</sup> Robert J. MacInnis,<sup>18,40</sup> Sergi Castellví-Bel,<sup>17</sup> Shuji Ogino,<sup>12,61,69,70</sup> Sonja I. Berndt,<sup>35</sup> Stéphane Bézieau,<sup>71</sup> Stephen N. Thibodeau,<sup>72</sup> Steven J. Gallinger,<sup>73</sup> Syed H. Zaidi,<sup>74</sup> Tabitha A. Harrison,<sup>1</sup> Temitope O. Keku,<sup>75</sup> Thomas J. Hudson,<sup>74</sup> Veronika Vymetalkova,<sup>53,54,55</sup> Victor Moreno,<sup>63,76,77,78</sup> Vicente Martín,<sup>76,79</sup> Volker Arndt,<sup>3</sup> Wei-Qi Wei,<sup>80</sup> Wendy Chung,<sup>81,82</sup> Yu-Ru Su,<sup>1</sup> Richard B. Hayes,<sup>83</sup> Emily White,<sup>1,84</sup> Pavel Vodicka,<sup>53,54,55</sup> Graham Casey,<sup>85</sup> Stephen B. Gruber,<sup>86</sup> Robert E. Schoen,<sup>87</sup> Andrew T. Chan,<sup>11,12,36,60,61,88</sup> John D. Potter,<sup>1,89</sup> Hermann Brenner,<sup>3,90,91</sup> Gail P. Jarvik,<sup>4,92</sup> Douglas A. Corley,<sup>2</sup> Ulrike Peters,<sup>1,84,\*</sup> and Li Hsu<sup>1,93,\*</sup>

occurred in the United States (US) in 2019.<sup>2</sup> Better treatments have improved survival rates but achieving higher uptake and adherence to CRC screening could more rapidly reduce morbidity and mortality.<sup>2,3</sup> US 5-year rela-

tive survival for individuals with advanced stage cancers is below 15%, whereas individuals with cancers detected early have 5-year relative survival approaching 90%.<sup>2</sup> For those detected with adenomas, survival is essentially

d/Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EHD), University of Barcelona, Barcelona 08007, Spain; <sup>18</sup>Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3000, Australia; <sup>19</sup>Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; <sup>20</sup>University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA; <sup>21</sup>Cincinnati VA Medical Center, Cincinnati, OH 45229, USA; <sup>22</sup>Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå 90187, Sweden; <sup>23</sup>Wallenberg Centre for Molecular Medicine, Umeå University, Umeå 90187, Sweden; <sup>24</sup>SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; <sup>25</sup>Department of General Surgery, University Hospital Rostock, Rostock 18051, Germany; <sup>26</sup>Huntsman Cancer Institute and Department of Population Health Sciences, University of Utah, Salt Lake City, UT 84112, USA; <sup>27</sup>Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS2 9JT, UK; <sup>28</sup>University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC 3010, Australia; <sup>29</sup>Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC 3010, Australia; <sup>30</sup>Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC 3010, Australia; <sup>31</sup>Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; <sup>32</sup>School of Public Health, Imperial College London, London SW7 2AZ, UK; <sup>33</sup>Translational Genomics Research Institute - An Affiliate of City of Hope, Phoenix, AZ 85003, USA; <sup>34</sup>Department of Bioinformatics and Medical Education, University of Washington Medical Center, Seattle, WA 98195, USA; <sup>35</sup>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; <sup>36</sup>Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA; <sup>37</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02108, USA; <sup>38</sup>Kaiser Permanente Washington Research Institute, Seattle, WA 98101, USA; <sup>39</sup>Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; <sup>40</sup>Cancer Epidemiology Division, Cancer Council Victoria, 615 St Kilda Road, Melbourne, VIC 3004, Australia; <sup>41</sup>Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC 3168, Australia; <sup>42</sup>Division of Human Genetics, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA; <sup>43</sup>Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; <sup>44</sup>Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA; <sup>45</sup>School of Public Health, Oregon Health & Science University, Portland, OR 97239, USA; <sup>46</sup>Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, 69120 Germany; <sup>47</sup>University Medical Centre Hamburg-Eppendorf, University Cancer Centre Hamburg (UCC), Hamburg 20246, Germany; <sup>48</sup>Department of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden 01062, Germany; <sup>49</sup>Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; <sup>50</sup>Department of Medicine, Weill Cornell Medical College, NY 10065, USA; <sup>51</sup>Department of Family Medicine, University of Virginia, Charlottesville, VA 22903, USA; <sup>52</sup>University of Hawaii Cancer Center, Honolulu, HI 96813, USA; <sup>53</sup>Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, 142 20 Prague 4, Czech Republic; <sup>54</sup>Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic; <sup>55</sup>Faculty of Medicine and Biomedical Center in Pilsen, Charles University, 323 00 Pilsen, Czech Republic; <sup>56</sup>Nutrition and Metabolism Section, International Agency for Research on Cancer, World Health Organization, Lyon 69372, France; <sup>57</sup>Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA; <sup>58</sup>PanCuRx Translational Research Initiative, Ontario, Institute for Cancer Research, Toronto, ON M5G0A3, Canada; <sup>59</sup>Memorial University of Newfoundland, Discipline of Genetics, St. John's, NL A1B 3R7, Canada; <sup>60</sup>Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA; <sup>61</sup>Broad Institute of Harvard and MIT, Cambridge, MA 02141, USA; <sup>62</sup>Department of Nutrition, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA; <sup>63</sup>Oncology Data Analytics Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona 08908, Spain; <sup>64</sup>Department of Health Science Research, Mayo Clinic, Scottsdale, AZ 85260, USA; <sup>65</sup>Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA; <sup>66</sup>Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0SR, UK; <sup>67</sup>Behavioral and Epidemiology Research Group, American Cancer Society, Atlanta, GA 30303, USA; <sup>68</sup>School of Public Health, University of Washington, Seattle, WA 98195, USA; <sup>69</sup>Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; <sup>70</sup>Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; <sup>71</sup>Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) Nantes, Nantes 44093, France; <sup>72</sup>Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA; <sup>73</sup>Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G1X5, Canada; <sup>74</sup>Ontario Institute for Cancer Research, Toronto, ON M5G0A3, Canada; <sup>75</sup>Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC 27599, USA; <sup>76</sup>CIBER Epidemiología y Salud Pública (CIBERESP), Madrid 28029, Spain; <sup>77</sup>Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona 08907, Spain; <sup>78</sup>ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Spain; <sup>79</sup>Biomedicine Institute (BIOMED), University of León, León 24071, Spain; <sup>80</sup>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; <sup>81</sup>Office of Research & Development, Department of Veterans Affairs, Washington, DC 20420, USA; <sup>82</sup>Departments of Pediatrics and Medicine, Columbia University Medical Center, New York, NY 10032, USA; <sup>83</sup>Division of Epidemiology, Department of Population Health, New York University School of Medicine, New York, NY 10016, USA; <sup>84</sup>Department of Epidemiology, University of Washington, Seattle, WA 98195, USA; <sup>85</sup>Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22903, USA; <sup>86</sup>Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA; <sup>87</sup>Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15219, USA; <sup>88</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA 02115, USA; <sup>89</sup>Centre for Public Health Research, Massey University, Wellington 6140, New Zealand; <sup>90</sup>Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg 69120, Germany; <sup>91</sup>German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany; <sup>92</sup>Genome Sciences, University of Washington Medical Center, Seattle, WA 98195, USA; <sup>93</sup>Department of Biostatistics, University of Washington, Seattle, WA 98195, USA

\*Correspondence: [upeters@fredhutch.org](mailto:upeters@fredhutch.org) (U.P.), [lih@fredhutch.org](mailto:lih@fredhutch.org) (L.H.)  
<https://doi.org/10.1016/j.ajhg.2020.07.006>.

100%. The guidelines for initiating CRC screening are currently based mainly on two risk factors: attained age and family history of CRC.<sup>4</sup> Use of these criteria results in substantial under- and over-utilization of CRC screening with associated harms, because more than 80% of all CRC cases occur in those without a positive family history in first-degree relatives. It is therefore important to improve risk prediction to inform screening and other prevention strategies. Risk prediction using data from genome-wide association studies (GWASs) has been proposed in Kooperberg et al.<sup>5</sup> Polygenic risk scores (PRS), such as those based on LDpred,<sup>6</sup> have shown great promise in improving prediction for complex disease risk. The study from Khera et al.<sup>7</sup> is part of an emerging corpus considering the plausibility of incorporating genome-wide PRS into disease screening within health care systems.<sup>8</sup> For coronary artery diseases, the PRS was able to identify 10 times more people at the same or higher risk than the conventionally used monogenic test that identifies about 2 out of 100 individuals with an OR > 3. They showed similar results for other diseases, such as type 2 diabetes or breast cancer. Those at high risk can potentially benefit from targeted interventions, such as lipid-lowering drugs, dietary interventions, or screening.<sup>7</sup>

Models have been developed and evaluated for prediction of CRC risk using known genetic susceptibility variants identified by GWASs.<sup>9–13</sup> The area under the receiver operating characteristics curve (AUC) has improved as more susceptibility variants are included with the most recent model that includes 63 known variants and family history yielding AUC = 0.59 for both men and women.<sup>9</sup> However, we found known variants identified to date explain only about 10% of the heritable fraction of CRC risk.<sup>14</sup> This suggests that substantial improvement in prediction could be achieved by using a genome-wide approach that includes many more single-nucleotide polymorphisms (SNPs) that, individually, may not reach the stringent threshold for genome-wide significance.<sup>15</sup>

Machine-learning techniques, such as support vector machines, penalized regression, neural networks, random forests, and the extreme gradient tree boosting approaches, have been applied to GWAS data.<sup>16–20</sup> Typically, these approaches require first reducing the number of genetic variants from millions to thousands and then building a risk-prediction model from selected variants with various machine-learning methods. For example, a widely used approach for dimension reduction involves linkage disequilibrium (LD)-based marker pruning or clumping<sup>21</sup> and applying a p value threshold to association statistics. As some of the familial aggregation of CRC is explained by a polygenic component, such dimension reduction based on p values may discard variants that individually have little predictive power but collectively have substantial predictive power. To account for this possibility, the LDpred method employs a Bayesian framework to jointly model all genetic variants of the genome in building the PRS without *a priori* dimension reduction.<sup>6</sup>

Using statistical and machine-learning techniques on GWAS data from more than 120,000 CRC-affected case subjects and control subjects of European ancestry, we address the question of whether a PRS that uses variants beyond known CRC risk-associated variants can improve discriminatory accuracy between CRC-affected case subjects and control subjects. We developed PRS using three different approaches, based on: (1) 140 known GWAS variants as the baseline model; (2) SNP selection followed by machine learning; and (3) LDpred. We then evaluated the performance of these scores externally in an independent contemporary community-based cohort of 101,987 study participants, including 72,791 of European ancestry.

## Material and Methods

### Datasets


#### Derivation Datasets

To develop an accurate CRC risk prediction model, we used GWAS data on 55,105 case subjects and 65,079 control subjects of European ancestry from large-scale research studies (~120,000 participants with genotype data on more than 40 million variants), including the Genetics and Epidemiology of CRC Consortium and Colon Cancer Family Registry (GECCO) with 29,864 case subjects and 31,629 control subjects, the CRC Transdisciplinary Study (CORECT) with 19,885 case subjects and 12,043 control subjects, and United Kingdom Biobank (UKB) with 5,356 case subjects and 21,407 control subjects. For more details such as study participant characteristics, genotyping, imputation, quality control, and single-variant association analyses, readers are referred to the [Supplemental Material and Methods](#) (Section 3 and [Table S1](#)) and Huyghe et al.<sup>14</sup> Briefly, the average age was 62 years (standard deviation [SD] = 11 years). About 52% were men and 11% had a positive family history of CRC in first-degree relatives. Our primary analysis was focused on individuals of European ancestry due to insufficient numbers of CRC cases among other ancestral groups.

#### Evaluation Dataset

The risk prediction models were externally evaluated in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, an independent contemporary cohort including 101,987 genotyped participants ( $\geq 18$  years old) nested within the Kaiser Permanente Northern California (KPNC) integrated healthcare delivery system.<sup>22</sup> Participants provided a saliva sample and broadly consented to the research use of their DNA and mailed survey data, which was then linked to selected data from electronic health records. Of note, this cohort was not used in any prior discovery of CRC risk variants and, hence, provides the opportunity for an independent evaluation. Details on the genotyping array, quality control, and imputation have been described previously<sup>23</sup> and in the [Supplemental Material and Methods](#) (Section 4 and [Table S3](#)).

As the model building was limited to case and control subjects of European descent defined by genetic clustering with Europeans from HapMap, we also restricted the primary analysis to the genetically defined European subsets ( $n = 72,791$ , 42,520 men and 30,271 women), which included 1,311 CRC cases, 3,949 advanced adenoma cases (AA), 13,472 adenoma cases, and 10,730 individuals with hyperplastic polyps. A personal history of cancer was determined from cancer-registry data and



**Figure 1. Description of Three Approaches to Derive Polygenic Risk Scores (PRS) for Colorectal Cancer**

electronic-health-record data. A family history of CRC was ascertained by integrating data from baseline surveys and electronic health records (i.e., diagnosis codes, family history documentation). About 9.6% of participants (n = 7,029) had a positive family history in first-degree relatives. Hyperplastic polyps, AA, and non-AA were identified using Systematized Nomenclature of Medicine (SNOMED) pathology codes and validated using natural language processing.<sup>24</sup> We defined an AA as any adenoma with villous histology or which was 10 mm in size or greater. The cohort was unselected for any disease phenotype and GERA participants were not asked to engage in specific medical or screening tests for research purposes. However, given the age distribution of the GERA participants (median age at baseline = 52 years with median follow-up 21 years), 70% of population has undergone screening for CRC as part of their usual care, either by fecal immunochemical testing (FIT, 38%) or endoscopy (sigmoidoscopy or colonoscopy, 58%). All study participants provided written informed consent and the study was approved by the KPNC Institutional Review Board.

#### Validation Dataset

We further validated the models in an independent study, the Electronic Medical Records and Genomics (eMERGE) (n = 83,717). The details of the study were described elsewhere.<sup>25</sup> A brief description of the genotyping array, quality control, and imputation is provided in [Supplemental Material and Methods](#) (Section 5). The colorectal cancer case subjects were defined as those who had at least two ICD9/10 codes for CRC. Control subjects had zero ICD9/10 codes for CRC. Participants with a single ICD9/10 code for CRC were excluded from analysis. Adults over age 18 years who had confirmed European ancestry and no missing age were included in the validation dataset, resulting a total of 38,214 participants. The characteristics of these participants are provided in [Table S10](#).

#### Polygenic Risk Score Derivation

PRS provides a quantitative measure of an individual's inherited risk based on the cumulative impact of many genetic risk variants. Each variant is scored based on the number of variant alleles an individual carries (e.g., zero, one, or two copies). The individual variant scores are then weighted according to the strength and direction of their association with disease and finally summed to give a single risk score. Imputed variants are scored by expected number of variant alleles (i.e., dosage). We studied three approaches for constructing PRS. [Figure 1](#) depicts the summary of these different PRS derivation strategies. The weights for Approach 1 of known loci are provided in [Table S4](#). As the number of variants for the other two approaches are very large, the weights for these variants are available upon request from the authors.

#### Approach 1: Known GWAS Variants

Using GWAS, we and others have identified 140 SNPs that were independently associated with CRC risk<sup>14</sup> and references therein.<sup>26,27</sup> All but three were present in the GERA dataset. For the three missing SNPs, we selected surrogates based on LD and the p value of univariate association analysis. The surrogates are provided in [Table S4](#).

We calculated the PRS as a weighted sum of risk alleles  $\sum_i \hat{\beta}_i x_i$ , where  $x_i$  is the expected number of risk alleles and  $\hat{\beta}_i$  is the log-odds ratio (OR) estimate of single-variant association from the previously published results that first reported the variants or meta-analysis results of our datasets. The meta-analysis adjusted for age, sex, study, and principal components (PCs) to account for population substructure. For the SNPs discovered in the data from this consortium, we adjusted for the winner's curse.<sup>28</sup> We provided the details of meta-analysis in Section 3.3, [Supplemental Material and Methods](#).



### Approach 2: SNP Selection and Machine Learning

In this approach, we first selected a subset of SNPs using LD clumping and p value thresholding and then built risk-prediction models using machine learning. To avoid overfitting, we divided the derivation datasets into two non-overlapping sets, one for SNP selection and the other for model building.

**SNP Selection.** We used GWAS data from GECCO (29,864 case subjects and 31,629 control subjects) and performed univariate association analysis, adjusting for age, sex, study, and PCs to account for population substructure. To remove highly correlated SNPs, we performed LD-clumping using the LD-driven p value clumping procedure in PLINK v.1.90b (-clump).<sup>29</sup> In this process, the algorithm generates clumps around index SNPs with p values less than an *a priori* defined threshold. Each clump contains all SNPs that are in LD with the index SNP, within 500 kilobases, as determined by pairwise correlation ( $R^2$ ) threshold. The algorithm iteratively cycles through all index SNPs, beginning with the smallest p value, only allowing each index SNP to appear in one clump (non-overlapping). The final output contains the most statistically significant disease-associated SNP for each LD-based clump across the genome. To identify the optimal p value cut-off and LD- $R^2$  value, we chose a wide range of p value thresholds, from  $5 \times 10^{-8}$  to 0.01, and two  $R^2$  values, 0.02 and 0.2, to select SNPs and calculated the corresponding PRS summing these SNPs weighted by the log-OR estimates, where the log-OR is the log-odds ratio estimate of univariate association analysis using GECCO data. We then used the UKB data (5,356 case subjects and 21,407 control subjects) to evaluate the discriminatory accuracy of these PRS (Figure S1). The AUC reached the maximum when  $R^2 = 0.02$  and p value =  $1 \times 10^{-3}$ . At this threshold, we had about 15,000 SNPs. We then explored further the number of SNPs ranging from 1,000 up to 50,000 and calculated the PRS by adding SNPs in the incremental order of p values. The AUC of the PRS peaked when the number of SNPs was at around 10,000 SNPs, which were used for the subsequent model building.

**Model Building.** Based on these selected SNPs we developed prediction models using machine-learning algorithms, using data from CORECT on 19,885 case subjects and 12,043 control subjects. We used two complementary machine-learning approaches, penalized generalized linear regression<sup>30</sup> and XGBoost.<sup>31</sup> We obtained the optimal values of the tuning parameters using 10-fold cross validation and re-estimated the regression coefficients using the entire CORECT data at the optimal tuning parameter values.

We performed penalized regression including both the known GWAS variants PRS and top SNPs from the SNP-selection step adjusting for age, sex, genotyping phase, and PCs. The confounders and known GWAS variants PRS were not penalized. We calculated the overall PRS by summing the known loci PRS and  $\sum_{i=1}^N \hat{\beta}_i x_i$ , where  $x_i$  is the  $i^{\text{th}}$  selected SNP and  $\hat{\beta}_i$  is the corresponding regression coefficient estimate from penalized regression. We performed ridge, lasso and elastic net penalized regression. We used the R package glmnet for the ridge and lasso regression and caret for the elastic net.

XGBoost<sup>31</sup> is based on gradient boosted decision trees, which, in contrast to penalized regression methods, incorporate complex non-linear interactions into prediction models in a non-additive form. Boosting is a powerful ensemble learning algorithm in which weak classifiers are added sequentially to correct the errors made by existing classifiers toward building a strong classifier. As in the penalized regression, we included both the known loci PRS and top SNPs from the SNP-selection step. The PRS from XGBoost is the classifier that gives the smallest misclassification

error in cross-validated datasets. We derived the model using the R package XGBoost, a fast and efficient implementation of the gradient tree boosting method.

### Approach 3: LDpred

LDpred<sup>6</sup> is a Bayesian genetic risk prediction method, developed for genome-wide genetic risk prediction, which takes into account LD among the markers (SNPs). In an infinitesimal model, all markers are assumed to be causal and the marker effects follow a normal distribution, i.e.,  $\beta_i \sim N(0, (n^2/M))$ ,  $i = 1, \dots, M$ , where  $M$  is the total number of markers and  $h^2$  is the total heritability explained by the markers. In the non-infinitesimal model, only a fraction of the  $M$  markers is assumed to be causal. A Gaussian-mixture prior is assumed in which  $\beta_i \sim N(0, (n^2/M_p))$  with probability  $\rho$  and  $\beta_i \sim 0$  with probability  $(1 - \rho)$ . LDpred computes the posterior mean effects of markers, taking into account the LD structure.

We used summary statistics from all GWASs, including GECCO, CORECT, and UKB, and calculated LD using the genotypes from a subset of our samples (29,305 case subjects and 31,727 control subjects) to reduce computational burden; this far exceeded the at least 2,000 individuals as suggested by LDpred. We further restricted the genetic markers to the HapMap3 panel to circumvent the non-convergence issue from training on summary statistics of very large sample sizes. LDpred requires a prior specification of  $\rho$ , the fraction of causal variants. Because  $\rho$  is generally unknown, we used a range of values for  $\rho$ : 1.0, 0.3, 0.1, 0.03, 0.01, 0.005, 0.003, and 0.001, the default values recommended by LDpred. A total of 8 candidate PRS were derived. The analysis was performed using the software LDpred.

### Evaluation of Model Performance in an Independent Cohort

We evaluated the discriminatory accuracy of PRS derived from the three approaches described above in the GERA cohort by calculating the AUC.<sup>32</sup> Our primary outcome was CRC in European ancestry. We compared CRC case subjects with control subjects who did not have CRC or any precursor lesions, including AA, adenomas, or hyperplastic polyps. As a secondary analysis, we evaluated the AUC for AA, non-AA, and hyperplastic polyps, respectively. As sensitivity analyses, we estimated AUC using control subjects who also had precursor lesions in a sequential manner: that is, for the CRC analysis, control subjects included any precursor lesion; for AA, control subjects included adenoma and hyperplastic polyps; and for adenoma, control subjects included hyperplastic polyps. In addition, we estimated the AUCs stratified on first-degree family history (yes/no), sex (men/women), and other race/ethnicity (Asian, Hispanic, and African American). We adjusted for age (at diagnosis for case subjects and at last observation for control subjects) and sex in all AUC estimations and obtained the 95% confidence intervals by bootstrap resampling. The p values for comparing the AUC estimates between different models or groups were also obtained via bootstrap methods. A total of 500 bootstrap datasets were generated.

We performed the Cox proportional hazards model for CRC and obtained estimates of hazard ratios (HRs) and 95% confidence intervals (CI) by comparing the top percentiles (0.5%, 1%, 5%, 10%, 20%, and 30%) with the remaining percentiles (99.5%, 99%, 95%, 90%, 80%, and 70%) of PRS using Cox proportional hazards regression. Observation time was defined as the earliest of the following times: age at CRC diagnosis, death, or last follow-up. The disease status was 1 if the individual developed CRC and

**Table 1. AUC Comparisons of CRC versus Control Subjects for PRS Derived via Three Different Approaches in the Independent GERA Cohort**

PRS Derivation Strategy	n Variants	AUC (95% CI)	
<b>Approach 1: Known GWAS Variants</b>			
Known variants	140	0.629 (0.613–0.645)	
<b>Approach 2: SNP Selection and Machine Learning</b>			
Ridge	10,000	0.633 (0.617–0.648)	
Lasso	10,000	0.629 (0.601–0.646)	
Elastic Net	10,000	0.630 (0.612–0.641)	
XGBoost	10,000	0.629 (0.614–0.643)	
<b>Approach 3: LDpred</b>			
LDpred	$\rho = 1$	1,180,765	0.620 (0.603–0.637)
	$\rho = 0.3$	1,180,765	0.625 (0.608–0.642)
	$\rho = 0.1$	1,180,765	0.628 (0.611–0.645)
	$\rho = 0.03$	1,180,765	0.635 (0.619–0.651)
	$\rho = 0.01$	1,180,765	0.646 (0.630–0.662)
	$\rho = 0.005$	1,180,765	0.649 (0.633–0.664)
	$\rho = 0.003$	1,180,765	0.654 (0.639–0.669)
	$\rho = 0.001$	1,180,765	0.643 (0.628–0.658)

For LDpred,  $\rho$  is the proportion of genetic variants assumed to be causal for CRC.

0 otherwise. As individuals joined GERA at different ages, we treated age at starting membership as left truncated.

We estimated age-dependent disease incidences for CRC and advanced neoplasia (CRC and AA), stratified by the top 5% and bottom 5% of PRS by 1 minus the Kaplan-Meier estimator. For advanced neoplasia, the observation time was defined as the earliest of the following times: age at CRC diagnosis, AA, death, or last follow-up, and the disease status was 1 if the individual developed CRC or AA and 0 otherwise.

To gauge the potential clinical impact of PRS, we calculated the proportion of case subjects and probabilities of developing CRC by age 80, stratified by the deciles of LDpred-derived PRS. In addition, we estimated the proportion of case subjects in the top 10%, 20%, and 30% and the bottom 10%, 20%, and 30% of PRS both alone and together with family history.

We used the R packages survival for the survival analysis and survminer for the plots.

## Results

### Discriminatory Accuracy of Risk Prediction Models

There were 1,311 CRC case subjects and 53,722 control subjects in the GERA cohort. The AUC estimate for Approach 1 of 140 known GWAS variants was 0.629 with 95% confidence interval (CI): 0.613–0.645 (Table 1). In Approach 2, we selected a total of 10,000 SNPs, based on which we built prediction models using penalized linear regression and XGBoost. Ridge regression produced an AUC estimate of 0.633 (95% CI 0.617–0.648), slightly bet-

ter than lasso (AUC 0.630, 95% CI 0.601–0.646) and elastic net (AUC 0.629, 95% CI 0.612–0.641). XGBoost had a similar AUC estimate: 0.629 (95% CI 0.614–0.643). Approach 3, LDpred, had the best performance when the fraction of causal variants ( $\rho$ ) = 0.003, producing an AUC estimate of 0.654 (95% CI 0.639–0.669). This was a substantial improvement (4% increase in AUC) over both Approach 1 (p value = 0.010) and Approach 2 (p value = 0.010 for both ridge regression and XGBoost).

We further calculated the AUC of the best performing model for each approach stratified by family history and sex (Table S5). All models had statistically significantly greater AUC estimates in individuals with a positive family history than those without (the p values are 0.021, 0.020, and 0.021 for Approaches 1, 2, and 3, respectively) and there is no significant difference in AUC estimates between men and women (p values > 0.05 for all models).

In addition to CRC, we evaluated the performance of the models for advanced neoplasia, as well as CRC precursor lesions separately: AA, adenoma, and hyperplastic polyps in Europeans (Table S5). The AUC estimate of LDpred for the advanced neoplasia was 0.629 (95% CI 0.620–0.637), close to the AUC estimate for AA, as it was mainly driven by the large number of AA compared to CRC case subjects. All models showed some discriminatory accuracy between various precursor lesions compared with control subjects; however, the accuracy was sequentially reduced compared with the model for CRC. Again, LDpred had the best performance among the three approaches. As a sensitivity analysis, we assessed the AUC where the control subjects also included precursor lesions (Table S6). The AUC estimates were all reduced, but the reduction was modest ranging from 0.01 to 0.02, and the AUC still showed a sequential decrease across CRC, AA, adenoma, and hyperplastic polyps.

We estimated the AUC of the PRS among Asians (96 CRC case subjects and 5,758 control subjects), Hispanics (70 CRC case subjects and 5,221 control subjects), and African Americans (56 CRC case subjects and 2,409 control subjects). All models performed more poorly for these demographic groups than for Europeans, whether for CRC, AA, adenoma, or hyperplastic polyps (Table S7). For example, the AUC estimates of LDpred for CRC were 0.601 (95% CI 0.538–0.664), 0.602 (95% CI 0.500–0.624), and 0.543 (95% CI 0.542–0.662) for Asians, Hispanics, and African Americans, respectively, which were considerably poorer than for Europeans.

### Association of PRS with Age of Diagnosis of CRC

Focusing on the best model for each approach, we estimated the HR and 95% CI for individuals in the top 30%, 20%, 10%, 5%, 1%, and 0.5% of the PRS compared with the remaining individuals (Table 2). Individuals in the top 1% of LDpred-derived PRS distribution had 2.68-fold increased CRC risk (95% CI 1.82–3.96) compared with the remaining 99% of the individuals. In contrast, the PRS from ridge regression identified only 0.5% of

**Table 2. Hazard Ratio Estimates (95% Confidence Intervals) of CRC for PRS Derived from Three Different Approaches**

	Approach 1		Approach 2		Approach 3	
	HR (95% CI)	p Value	HR (95% CI)	p Value	HR (95% CI)	p Value
Top 30% versus remaining	1.92 (1.75–2.23)	$<2 \times 10^{-16}$	1.94 (1.72–2.19)	$<2 \times 10^{-16}$	2.19 (1.94–2.47)	$<2 \times 10^{-16}$
Top 20% versus remaining	1.96 (1.73–2.23)	$<2 \times 10^{-16}$	2.07 (1.82–2.35)	$<2 \times 10^{-16}$	2.42 (2.14–2.74)	$<2 \times 10^{-16}$
Top 10% versus remaining	2.08 (1.82–2.70)	$<2 \times 10^{-16}$	2.26 (1.95–2.63)	$<2 \times 10^{-16}$	2.54 (2.20–2.95)	$<2 \times 10^{-16}$
Top 5% versus remaining	2.13 (1.63–2.69)	$<2 \times 10^{-16}$	2.36 (1.95–2.86)	$4.9 \times 10^{-15}$	2.56 (2.12–3.09)	$<2 \times 10^{-16}$
Top 1% versus remaining	2.15 (1.17–2.90)	$8.3 \times 10^{-3}$	2.34 (1.56–3.51)	$3.7 \times 10^{-5}$	2.68 (1.82–3.96)	$6.6 \times 10^{-07}$
Top 0.5% versus remaining	2.21 (1.16–3.81)	$1.0 \times 10^{-2}$	2.77 (1.64–4.69)	$1.5 \times 10^{-3}$	2.82 (1.66–4.79)	$9.7 \times 10^{-04}$

Approach 1: known GWAS variants; Approach 2: SNP selection and machine learning (ridge regression); Approach 3: LDpred with  $\rho = 0.003$ .

individuals with a similar HR estimate. The estimates for the known GWAS variants were smaller for the same top 0.5%. Furthermore, LDpred identified more than 30% of individuals without a family history of CRC (Table S8) as having about 2.2-fold higher risk of CRC, similar to that of those with a first-degree family history of CRC. In contrast, the ridge regression identified 10%, and the known GWAS variants 5%, of these individuals as being at this level of risk.

### Assessing CRC Probabilities for PRS

We estimated age-specific probabilities for developing CRC and advanced neoplasia by age 80 by percentile of PRS (Figure 2). Individuals in the top 5% of PRS (high risk) from LDpred had 7.5% (95% CI 5.6%–8.3%) and 23.5% (95% CI 21.3%–25.7%) probabilities of developing CRC and advanced neoplasia, respectively. In contrast, the probabilities for individuals in the bottom 5% of PRS (low risk) were 0.7% (95% CI: 0.1%–1.0%) and 4.3% (95% CI: 3.3%–5.3%), respectively.

We calculated the proportion of cases stratified by the deciles of LDpred-derived PRS and the corresponding disease probabilities by age 80 (Figure 3). The proportion of cases that fell in the highest decile of PRS was 23.4% (95% CI: 19.8%–27.0%); in contrast, the proportion of cases in the lowest decile was 3.3% (95% CI: 2.0%–4.6%) (Table 3).

We also estimated the disease probabilities stratified by family history of CRC (Figure S2) and advanced neoplasia (Figure S3). There was substantial variation in advanced neoplasia probabilities for top 5% and bottom 5%, even among those with a positive family history. For example, individuals with a positive family history but with LDpred-derived PRS in the low-risk group (bottom 5%) had lower lifetime risk (~8.0% by age 80) than individuals at average risk but without a family history (~12%). On the other hand, individuals with a positive family history and a LD-derived PRS in the high-risk group (top 5%) had a lifetime risk of about 35%. In general, compared with the PRS based on known GWAS variants, the LDpred-derived PRS showed a greater separation in disease probabilities between the high-risk and low-risk group and, among high-


risk groups, between those with and without a family history.

Taking into account both PRS and family history simultaneously, 18.0% of individuals were either in the top 10% of PRS or had a positive family history in the cohort but constituted 39.3% of case subjects (95% CI 38.9%–39.8%) (Table 3). On the other hand, 9.1% of individuals were in the bottom 10% of PRS and had no positive family history but constituted only 2.3% of case subjects (95% CI 1.9%–2.8%). The proportion of case subjects with a positive family history was 21.0% (95% CI 19.3%–21.4%).

We further validated the LDpred models using eMERGE data. The pattern of AUC estimates for LDpred models were consistent to the results in GERA cohort; however, the AUC estimates were overall weaker. Specifically, LDpred  $\rho = 0.005$  had the best AUC 0.629 followed closely by LDpred  $\rho = 0.003$  with AUC 0.628, both of which improved substantially compared to the AUC for the known 140 GWAS loci (AUC = 0.591) (Table S11).

### Discussion

It is important to be able to identify individuals at high risk of CRC to enable enhanced screening and other interventions, including dietary recommendations, weight loss, and physical activity. Equally pressing is the need to identify individuals at low risk to prevent unnecessary screening and associated complications. As CRC has a sizable heritable fraction<sup>33</sup> and is polygenic in nature with probably thousands of genetic variants contributing to its development,<sup>34</sup> utilizing genome-wide data to predict risk holds promise for risk stratification for primary and secondary prevention. Our study comprehensively explores the predictive power for CRC of genome-wide genetic data, using the largest available resources including more than 120,000 CRC case subjects and control subjects of European ancestry with individual-level genetic data for model building and an independent cohort study of more than 100,000 genotyped participants for evaluation. We show that the LDpred approach including 1.2 M variants substantially improves the discriminatory accuracy over an approach that includes only 140 known GWAS



**Figure 2. Disease Probabilities for Developing CRC and Advanced Adenoma**

Probabilities of developing CRC (left) and advanced neoplasia (right) by age for PRS in the top 5% and bottom 5%, based on models derived from three approaches: known GWAS variants (Approach 1), SNP selection + machine learning with ridge regression (Approach 2), and LDpred with  $\rho = 0.003$  (Approach 3). Average is the overall age-specific CRC (left) and advanced neoplasia (right) probabilities for the GERA.

variants. In contrast, using a combination of SNP selection and machine learning shows little improvement over the known GWAS variants. To our knowledge, the LDpred-derived PRS has the best performance of any existing CRC genetic-risk-prediction model.

Although the improvement of the AUC from 0.629 to 0.654 may not appear marked (the improvement is 4%), the AUC is an average measurement and it is critical to evaluate the model with other measures to gauge the clinical impact of the model. For example, the LDpred-derived PRS identified the top 30% of the study population as having a relative risk of  $\sim 2.2$ , which is similar to that associated with having an affected first-degree relative.<sup>14,26</sup> For individuals with an affected first-degree relative, some guidelines recommend initiation of screening with colonoscopy at an earlier age. In contrast, the PRS based on the known GWAS variants identified  $<5\%$  as having a similar relative risk, demonstrating clearly the substantial improvement of the LDpred-derived PRS. It is important to note that only 10.5% of those individuals who were in the top 30% risk based on LDpred-derived PRS had a family history of CRC, demonstrating that the LDpred-derived PRS can potentially identify a larger fraction of the study population at high risk than family history alone. This means that  $\sim 27\%$  ( $89.5\% \times 30\%$ ) of the population who are classified as average risk based on current guidelines might benefit from earlier screening. As the PRS is a continuous variable, it allows for tailored recommendation, including a specified age of starting screening,<sup>9,26</sup> rather than simply defining a single high-risk group based on family history that, as we show, is itself heterogeneous.


In Approach 2, if we were to use the same dataset for feature selection and model development, there would be overfitting in the model development, which result in a worse performance in an independent dataset (Supplemental Material and Methods Section 6.1 and Table S9). To mitigate this overfitting, we thus split the data in two sets in the training step. The downside is that there is potential power loss for feature selection due to smaller sample size used in calculating the test statistics compared to the entire dataset as used in Approach 3. Nevertheless,

we expect that when the sample size of studies continues to rise, Approach 2 will be further improved. Our observations here are not unique to genome-wide risk prediction for colorectal cancer (see Chatterjee et al.,<sup>15</sup> Abraham et al.,<sup>18</sup> Evans et al.,<sup>35</sup> Yang et al.,<sup>36</sup> de Vlaming and Groenen,<sup>37</sup> and Malo et al.<sup>38</sup> for examples).

The LDpred approach, which builds a risk prediction model based on the entire genome, yielded better predictive performance than the approach that initially selected features before applying machine-learning algorithms. It is likely that the derivation dataset that we used for SNP selection is still too small given the large number of features (40M genetic variants) and weak effect sizes. As a result, performing SNP selection may lead to a substantial loss of information that cannot be compensated for, even with machine-learning algorithms like XGBoost. A potential limitation of LDpred is the assumption of additive effects only, whereas machine-learning approaches, such as XGBoost and random forest, can accommodate more complex non-linear effects but are not readily applicable to ultra-high dimensional data. Approaches such as deep learning that can handle ultra-high dimensional data may have potential to further improve the accuracy of prediction.

Including only the known GWAS variants (Approach 1) is simplest computationally. The SNP selection in Approach 2 also reduces computation time substantially. LDpred is the most computationally intensive due to the Monte Carlo Markov Chain (MCMC) procedure. It took  $\sim 4$  days for LDpred to compute the regression weights for each parameter setting, using our computing infrastructure, which has a node of 20 cores with 768 GB memory across all cores. Although LDpred is more computationally intensive than the other two PRS approaches, the implementation of the LDpred-derived PRS into electronic health record (EHR) data, once genome-wide array or sequencing data are available, will not be much more difficult. For example, it took  $\sim 6$  h to calculate the LDpred-derived PRS for 100,000 individuals in the GERA cohort. As these scores need to be calculated only once (although updates for improved models are likely), they





**Figure 3. Disease Probabilities and Proportion of Cases (95% CI) Subjects Stratified by the Deciles of LDpred-Derived PRS**

can be calculated upfront and stored as part of individual records like any other measurements (e.g., BMI, serum cholesterol). The more substantial challenge to implementation is perhaps the storage of genotype or sequencing data in a structured data object that is readily available to the EHR. To date, this challenge has not been solved in a standardized way;<sup>39,40</sup> however, the increasing clinical utility of PRS may motivate more rapid adoption of standardized integration of genotype and sequencing information into EHRs, which would serve as a foundation for implementation of a wide array of stratified-medicine tools.

Our study's large sample size likely is an important factor for the improved performance of the LDpred approach. Further, having access to an independent cohort that has not been included in any previous discoveries is key to provide an unbiased evaluation of the models.

Ideally, CRC would be detected early, allowing easier removal, perhaps even as a precursor lesion with a lower risk of complications and without the need for additional treatment such as radiation or chemotherapy. Previous work has shown that a PRS with fewer than 50 known loci was associated with increased risk of precursor lesions.<sup>41,42</sup> Consistent with these previous reports, we showed here, in our independent cohort, that all three PRS approaches also predicted AA and, to a lesser extent, adenoma and hyperplastic polyps. It is notable that as

not all individuals have had endoscopy (colonoscopy or sigmoidoscopy); some control subjects in this study may have precursor lesions. As a result, the actual AUC is likely to be underestimated. Nevertheless, this decline can be expected, as the disease generally progresses from hyperplastic polyps or non-advanced adenomas to AA to CRC, with only a fraction of the precursor lesions giving rise to CRC.

There are several limitations of our PRS. First, they were built using individuals of European descent; hence, the models show substantially lower performance in other ancestral groups. This is not surprising due to the difference in LD across ancestral groups. To address this important issue, dedicated efforts focused on other major racial/ethnic populations (African Americans, Asians, and Hispanic/Latinos) are needed to develop unbiased PRS for these ancestral groups. Second, as CRCs are heterogeneous with different molecularly defined subtypes, another limitation of our study is treating CRC as a single entity. However, this problem is not easy to overcome, given the need for large sample sizes and the limited availability of CRC case subjects with detailed molecular characterization. Third, while we validated that the LDpred model with  $\rho = 0.003$  performed among the best models in an independent eMERGE study, the model needs to be further evaluated for calibration as our preliminary evaluation shows (Supplemental Material and Methods Section 6.2

**Table 3. Disease Probabilities (%) and Proportion of CRC Case Subjects (%) (95% CI) by Age 80 in High- and Low-Risk Groups**

LDPred-Derived PRS			LDPred-Derived PRS + FamilyHx		
PRS (%)	Disease Prob (95% CI) (%)	Prop of Cases (95% CI) (%)	PRS or Pos FamHx (%) <sup>a</sup>	Disease Prob (95% CI) (%)	Prop of Cases (95% CI) (%)
Top 10	6.4 (5.5–7.3)	23.4 (19.8–27.0)	18.0	5.9 (5.2–6.6)	39.3 (38.9–39.8)
20	5.4 (4.8–6.1)	39.7 (32.7–42.8)	26.7	5.3 (4.7–5.8)	51.7 (49.1–54.2)
30	4.6 (4.1–5.1)	50.3 (46.6–55.6)	35.6	4.7 (4.2–5.1)	60.7 (57.5–63.9)
PRS (%)	Disease Prob (95% CI) (%)	Prop of Cases (95% CI) (%)	PRS and Neg FamHx (%) <sup>b</sup>	Disease Prob (95% CI) (%)	Prop of Cases (95% CI) (%)
Bottom 10	0.9 (0.5–1.2)	3.3 (2.0–4.6)	9.1	0.7 (0.3–0.9)	2.3 (1.9–2.8)
20	1.1 (0.8–1.5)	8.1 (7.5–8.7)	18.4	0.9 (0.7–1.2)	6.1 (5.4–7.1)
30	1.4 (1.0–1.6)	15.3 (14.3–16.5)	27.6	1.0 (0.9–1.2)	10.1 (8.9–12.0)

<sup>a</sup>PRS or Pos. FamHx: individuals were in the top x% of PRS or had a positive family history.

<sup>b</sup>PRS and negative FamHx: individuals were in the bottom x% and had a negative family history.

and Table S12). Caution must be taken when evaluating the calibration to account for the differences in individual-level characteristics such as screening prevalence and lifestyle risk factors.

An important question remains about how far we can improve the predictive performance using genome-wide genetic data. To this end, we showed that the best normal mixture model for effect-size distribution of our genome-wide data of common variants (allele frequency > 5%) yielded a theoretical maximal AUC of 0.68,<sup>34</sup> suggesting that the AUC can be further improved perhaps by using more complex models, larger number of SNPs, larger sample sizes, or some combination of these. We attempted to use all 40M SNPs imputed to the Haplotype Reference Consortium (HRC) when building LDpred models; however, we ran into convergence problems and hence limited the presentation only to SNPs in HapMap. The maximal theoretical AUC of 0.68 does not include rare variants. Based on our HRC imputed data, we estimated that at least half of CRC heritability is due to variants with an allele frequency < 1% (note this does not include high-penetrance variants as these are too rare to be imputed).<sup>14</sup> Accordingly, it can be expected that incorporation of rare variants can further improve the predictive performance of genome-wide genetic prediction models. This is probably not surprising as hundreds of millions of rare variants exist in the genome.

Work from our group<sup>43–45</sup> and others<sup>45</sup> has demonstrated that functional categories of the genome contribute to the heritability of CRC and that most susceptibility loci are in enhancers that vary between tumor and nonmalignant tissue. Thus, including colorectal tissue-specific functional data, such as transcriptomic or epigenomic data, would allow us to narrow down to the variants that are more likely to influence CRC risk. Our future direction is to develop methods that combine different functional annotation scores enriched for heritability, which will be particularly important as we expand prediction to rare variants. Furthermore, we will combine the PRS with other predictive factors, such as age, sex, screening history,

high-penetrance genes, environmental/lifestyle risk factors, or biomarkers of early detection, which we expect, based on our previous analysis,<sup>9</sup> will further substantially improve risk prediction. The modifiable risk factors for the CRC are an important component of risk prediction because the best approach to primary prevention is avoidance or elimination of these risk factors. For secondary prevention, both genetics and modifiable risk factors would be helpful for determining optimal CRC screening timing and frequency.

An aim of precision/stratified medicine is to predict risk of diseases based on an individual's genetic makeup, which could, in principle, be done at birth. An important consequence of genetic risk prediction is the identification of high-risk individuals who would otherwise not be identified as high risk. Such knowledge could result in changes in healthcare management to mitigate risk with relatively low-cost lifestyle changes or preventive therapies for those at greater risk.<sup>46</sup> Additionally, genetic risk prediction can identify individuals at low risk who might otherwise be enrolled unnecessarily in more frequent screening or surveillance programs based on age, family history, or history of polyps. The interval between colonoscopies or the modality of screening or surveillance could be informed by PRS. Although the risk of colonoscopic perforation in the setting of cancer screening is not precisely known, estimates from diagnostic (in which there is a clinical suspicion of colorectal pathology) and therapeutic colonoscopies suggest perforations occur about once per 1,000 procedures.<sup>47–49</sup> Perforations are life threatening and often require laparotomy, suggesting that non-invasive screening modalities such as FIT are attractive alternatives, particularly in low-risk individuals. These are already used in other countries where population-based endoscopy screening is not available. Of course, in the US, endoscopy is not population-wide either, so the capacity to stratify individuals on screening methods appropriate to their risk should improve uptake, reduce costs, and reduce complications.

We expect that our model will be a useful first step toward prioritizing those at high risk for targeted screening or intervention and to design clinical trials to test prevention strategies in the high-risk group, particularly with the eye toward those below the age of 50 years given the rising rates of early-onset CRC. In the future, it is expected that detailed genome-wide genetic information will become part of electronic medical records of all individuals to calculate an individual PRS and identify those at high or low risk for any disease, perhaps as early as at birth. This information will allow targeted interventions such as lifestyle modifications, chemoprevention, and screening to prevent diseases or diagnose them early. Broad accessibility, dropping genotyping costs, and the need to account for an individual's risk factor profile to improve screening have provided transformative opportunities in personalized medicine. However, wide-scale adoption of PRS into clinical practice raises key ethical and scientific challenges. For example, as the current PRS has been developed in Europeans given that most GWASs are done in this population, it is substantially more predictive in Europeans compared to other populations, which will widen the health disparity gap. To overcome this major ethical and scientific challenge, it is critical that researchers invest time and effort in developing unbiased PRS across all major US populations. Furthermore, it is important to evaluate the acceptance and effectiveness of genetic testing for risk-stratified interventions among the broader population and health care providers. Cost effectiveness analysis will provide important insights to guide policies related to personalized medicine. In summary, we developed a PRS with substantially higher ability both to predict CRC risk and to identify those at high and low risk than the other two approaches. The proposed CRC PRS offers a way to improve CRC risk prediction, with the potential for translation to optimize clinical decision making.

### Data and Code Availability

The source data for the findings of this study are available as follows. Genotype data for GECCO and CORECT have been deposited in the database of Genotypes and Phenotypes (dbGaP) under accession numbers phs001078.v1.p1, phs001415.v1.p1, and phs001315.v1.p1. The UK Biobank data are publicly available upon successful application from the UK Biobank. Genotype data of GERA participants who consented to having their data shared with dbGaP are available from dbGaP under accession phs000674.v2.p2. The complete GERA data are available upon successful application to the KP Research Bank. Genotype data of eMERGE participants are available from dbGaP under the accession number phs001616.v1.p1.

The codes used for statistical analysis and generation of tables and figures are publicly available.

### Supplemental Data

Supplemental Data can be found online at <https://doi.org/10.1016/j.ajhg.2020.07.006>.

### Acknowledgments

A full list of funding and acknowledgments is provided in the [Supplemental Data](#).

### Declaration of Interests

The authors declare no competing interests.

Received: November 27, 2019

Accepted: July 13, 2020

Published: August 5, 2020

### Web Resources

dbGaP, <https://www.ncbi.nlm.nih.gov/gap>

Elastic Net, <https://cran.r-project.org/web/packages/caret/index.html>

KP Research Bank, <https://researchbank.kaiserpermanente.org/>

LDpred, [https://bitbucket.org/bjarni\\_vilhjalmsson/LDpred](https://bitbucket.org/bjarni_vilhjalmsson/LDpred)

PLINK 1.9, <http://www.cog-genomics.org/plink/1.9/>

Ridge and Lasso Regression, <https://cran.r-project.org/web/packages/glmnet/index.html>

ROct, <https://www.rdocumentation.org/packages/ROct/versions/0.9.5>

Survivor, <https://www.rdocumentation.org/packages/survival/versions/3.2-3>

Survminer, <https://www.rdocumentation.org/packages/survminer/versions/0.4.7>

UK Biobank, <https://www.ukbiobank.ac.uk/>

XGBoost, <https://www.rdocumentation.org/packages/xgboost/versions/1.1.1.1>

### References

1. Sandouk, F., Al Jerf, F., and Al-Halabi, M.H.D.B. (2013). Precancerous lesions in colorectal cancer. *Gastroenterol. Res. Pract.* **2013**, 457901.
2. Howlander, N., Noone, A.M., Krapcho, M., and Miller, D. (2019). SEER Cancer Statistics Review, 1975-2016 (Bethesda, MD: National Cancer Institute). [https://seer.cancer.gov/archive/csr/1975\\_2016/](https://seer.cancer.gov/archive/csr/1975_2016/).
3. Vogelaar, I., van Ballegooijen, M., Schrag, D., Boer, R., Winawer, S.J., Habbema, J.D.F., and Zauber, A.G. (2006). How much can current interventions reduce colorectal cancer mortality in the U.S.? Mortality projections for scenarios of risk-factor modification, screening, and treatment. *Cancer* **107**, 1624–1633.
4. Smith, R.A., Mettlin, C.J., Davis, K.J., and Eyre, H. (2000). American Cancer Society guidelines for the early detection of cancer. *CA Cancer J. Clin.* **50**, 34–49.
5. Kooperberg, C., LeBlanc, M., and Obenchain, V. (2010). Risk prediction using genome-wide association studies. *Genet. Epidemiol.* **34**, 643–652.
6. Vilhjálmsson, B.J., Yang, J., Finucane, H.K., Gusev, A., Lindström, S., Ripke, S., Genovese, G., Loh, P.-R., Bhatia, G., Do, R., et al.; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) study (2015). Modeling linkage disequilibrium increases accuracy of polygenic risk scores. *Am. J. Hum. Genet.* **97**, 576–592.

7. Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Natarajan, P., Lander, E.S., Lubitz, S.A., Ellinor, P.T., and Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat. Genet.* *50*, 1219–1224.
8. Schork, A.J., Schork, M.A., and Schork, N.J. (2018). Genetic risks and clinical rewards. *Nat. Genet.* *50*, 1210–1211.
9. Jeon, J., Du, M., Schoen, R.E., Hoffmeister, M., Newcomb, P.A., Berndt, S.I., Caan, B., Campbell, P.T., Chan, A.T., Chang-Claude, J., et al.; Colorectal Transdisciplinary Study and Genetics and Epidemiology of Colorectal Cancer Consortium (2018). Determining risk of colorectal cancer and starting age of screening based on lifestyle, environmental, and genetic factors. *Gastroenterology* *154*, 2152–2164.e19.
10. Hsu, L., Jeon, J., Brenner, H., Gruber, S.B., Schoen, R.E., Berndt, S.I., Chan, A.T., Chang-Claude, J., Du, M., Gong, J., et al.; Colorectal Transdisciplinary (CORECT) Study; and Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) (2015). A model to determine colorectal cancer risk using common genetic susceptibility loci. *Gastroenterology* *148*, 1330–9.e14.
11. Dunlop, M.G., Tenesa, A., Farrington, S.M., Ballereau, S., Brewster, D.H., Koessler, T., Pharoah, P., Schafmayer, C., Hampe, J., Völzke, H., et al. (2013). Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. *Gut* *62*, 871–881.
12. Ibáñez-Sanz, G., Díez-Villanueva, A., Alonso, M.H., Rodríguez-Moranta, F., Pérez-Gómez, B., Bustamante, M., Martín, V., Llorca, J., Amiano, P., Ardanaz, E., et al. (2017). Risk Model for Colorectal Cancer in Spanish Population Using Environmental and Genetic Factors: Results from the MCC-Spain study. *Sci. Rep.* *7*, 43263.
13. Smith, T., Gunter, M.J., Tzoulaki, I., and Muller, D.C. (2018). The added value of genetic information in colorectal cancer risk prediction models: development and evaluation in the UK Biobank prospective cohort study. *Br. J. Cancer* *119*, 1036–1039.
14. Huyghe, J.R., Bien, S.A., Harrison, T.A., Kang, H.M., Chen, S., Schmit, S.L., Conti, D.V., Qu, C., Jeon, J., Edlund, C.K., et al. (2019). Discovery of common and rare genetic risk variants for colorectal cancer. *Nat. Genet.* *51*, 76–87.
15. Chatterjee, N., Wheeler, B., Sampson, J., Hartge, P., Chanock, S.J., and Park, J.-H. (2013). Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. *Nat. Genet.* *45*, 400–405, e1–e3.
16. Wei, Z., Wang, K., Qu, H.-Q., Zhang, H., Bradfield, J., Kim, C., Frackleton, E., Hou, C., Glessner, J.T., Chiavacci, R., et al. (2009). From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. *PLoS Genet.* *5*, e1000678.
17. Moore, J.H., Asselbergs, F.W., and Williams, S.M. (2010). Bioinformatics challenges for genome-wide association studies. *Bioinformatics* *26*, 445–455.
18. Abraham, G., Kowalczyk, A., Zobel, J., and Inouye, M. (2013). Performance and robustness of penalized and unpenalized methods for genetic prediction of complex human disease. *Genet. Epidemiol.* *37*, 184–195.
19. Bureau, A., Dupuis, J., Hayward, B., Falls, K., and Van Eerde- wegh, P. (2003). Mapping complex traits using Random Forests. *BMC Genet.* *4* (Suppl 1), S64.
20. Goldstein, B.A., Hubbard, A.E., Cutler, A., and Barcellos, L.F. (2010). An application of Random Forests to a genome-wide association dataset: methodological considerations & new findings. *BMC Genet.* *11*, 49.
21. Martin, A.R., Daly, M.J., Robinson, E.B., Hyman, S.E., and Neale, B.M. (2019). Predicting polygenic risk of psychiatric disorders. *Biol. Psychiatry* *86*, 97–109.
22. Gordon, N.P. (2006). How does the adult Kaiser Permanente membership in Northern California compare with the larger community?. [https://divisionofresearch.kaiserpermanente.org/projects/memberhealthsurvey/SiteCollectionDocuments/comparison\\_kaiser\\_vs\\_nonKaiser\\_adults\\_kpnc.pdf](https://divisionofresearch.kaiserpermanente.org/projects/memberhealthsurvey/SiteCollectionDocuments/comparison_kaiser_vs_nonKaiser_adults_kpnc.pdf).
23. Kvale, M.N., Hesselson, S., Hoffmann, T.J., Cao, Y., Chan, D., Connell, S., Croen, L.A., Dispensa, B.P., Eshragh, J., Finn, A., et al. (2015). Genotyping informatics and quality control for 100,000 subjects in the genetic epidemiology research on adult health and aging (GERA) cohort. *Genetics* *200*, 1051–1060.
24. Lee, J.K., Jensen, C.D., Levin, T.R., Zaubler, A.G., Doubeni, C.A., Zhao, W.K., and Corley, D.A. (2019). Accurate identification of colonoscopy quality and polyp findings using natural language processing. *J. Clin. Gastroenterol.* *53*, e25–e30.
25. Gottesman, O., Kuivaniemi, H., Tromp, G., Faucett, W.A., Li, R., Manolio, T.A., Sanderson, S.C., Kannry, J., Zinberg, R., Basford, M.A., et al.; eMERGE Network (2013). The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. *Genet. Med.* *15*, 761–771.
26. Law, P.J., Timofeeva, M., Fernandez-Rozadilla, C., Broderick, P., Studd, J., Fernandez-Tajes, J., Farrington, S., Svinti, V., Palles, C., Orlando, G., et al.; PRACTICAL consortium (2019). Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nat. Commun.* *10*, 2154.
27. Lu, Y., Kweon, S.-S., Tanikawa, C., Jia, W.-H., Xiang, Y.-B., Cai, Q., Zeng, C., Schmit, S.L., Shin, A., Matsuo, K., et al. (2019). Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer. *Gastroenterology* *156*, 1455–1466.
28. Zhong, H., and Prentice, R.L. (2008). Bias-reduced estimators and confidence intervals for odds ratios in genome-wide association studies. *Biostatistics* *9*, 621–634.
29. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* *4*, 7.
30. Hastie, T., Tibshirani, R., and Friedman, J. (2009). *The elements of statistical learning*, Second Edition (Springer).
31. Friedman, J.H. (2001). Greedy function approximation: a gradient boosting machine. *Ann. Stat.* *29*, 1189–1232.
32. Heagerty, P.J., Lumley, T., and Pepe, M.S. (2000). Time-dependent ROC curves for censored survival data and a diagnostic marker. *Biometrics* *56*, 337–344.
33. Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., and Hemminki, K. (2000). Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. *N. Engl. J. Med.* *343*, 78–85.
34. Zhang, Y., Wilcox, A.N., Zhang, H., Choudhury, P.P., Easton, D.F., Milne, R.L., Simard, J., Hall, P., Michailidou, K., Dennis, J., et al. (2020). Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers. *Nat. Commun* *11*, 3353.
35. Evans, D.M., Visscher, P.M., and Wray, N.R. (2009). Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. *Hum. Mol. Genet.* *18*, 3525–3531.



36. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, D.R., Madden, P.A., Heath, A.C., Martin, N.G., Montgomery, G.W., et al. (2010). Common SNPs explain a large proportion of the heritability for human height. *Nat. Genet.* *42*, 565–569.
37. de Vlaming, R., and Groenen, P.J.F. (2015). The current and future use of ridge regression for prediction in quantitative genetics. *BioMed Res. Int.* *2015*, 143712.
38. Malo, N., Libiger, O., and Schork, N.J. (2008). Accommodating linkage disequilibrium in genetic-association analyses via ridge regression. *Am. J. Hum. Genet.* *82*, 375–385.
39. Masys, D.R., Jarvik, G.P., Abernethy, N.F., Anderson, N.R., Papanicolaou, G.J., Paltoo, D.N., Hoffman, M.A., Kohane, I.S., and Levy, H.P. (2012). Technical desiderata for the integration of genomic data into Electronic Health Records. *J. Biomed. Inform.* *45*, 419–422.
40. Hoffman, J.M., Haidar, C.E., Wilkinson, M.R., Crews, K.R., Baker, D.K., Kornegay, N.M., Yang, W., Pui, C.-H., Reiss, U.M., Gaur, A.H., et al. (2014). PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. *Am. J. Med. Genet. C. Semin. Med. Genet.* *166C*, 45–55.
41. Weigl, K., Thomsen, H., Balavarca, Y., Hellwege, J.N., Shrubsole, M.J., and Brenner, H. (2018). Genetic risk score is associated with prevalence of advanced neoplasms in a colorectal cancer screening population. *Gastroenterology* *155*, 88–98.e10.
42. Hang, D., Joshi, A.D., He, X., Chan, A.T., Jovani, M., Gala, M.K., Ogino, S., Kraft, P., Turman, C., Peters, U., et al. (2020). Colorectal cancer susceptibility variants and risk of conventional adenomas and serrated polyps: results from three cohort studies. *Int. J. Epidemiol.* *49*, 259–269.
43. Bien, S.A., Auer, P.L., Harrison, T.A., Qu, C., Connolly, C.M., Greenside, P.G., Chen, S., Berndt, S.I., Bézieau, S., Kang, H.M., et al.; GECCO and CCFR (2017). Enrichment of colorectal cancer associations in functional regions: Insight for using epigenomics data in the analysis of whole genome sequence-imputed GWAS data. *PLoS ONE* *12*, e0186518.
44. Su, Y.-R., Di, C., Bien, S., Huang, L., Dong, X., Abecasis, G., Berndt, S., Bezieau, S., Brenner, H., Caan, B., et al. (2018). A Mixed-Effects Model for Powerful Association Tests in Integrative Functional Genomics. *Am. J. Hum. Genet.* *102*, 904–919.
45. Hu, Y., Lu, Q., Powles, R., Yao, X., Yang, C., Fang, F., Xu, X., and Zhao, H. (2017). Leveraging functional annotations in genetic risk prediction for human complex diseases. *PLoS Comput. Biol.* *13*, e1005589.
46. De La Vega, F.M., and Bustamante, C.D. (2018). Polygenic risk scores: a biased prediction? *Genome Med.* *10*, 100.
47. Dafnis, G., Ekbom, A., Pahlman, L., and Blomqvist, P. (2001). Complications of diagnostic and therapeutic colonoscopy within a defined population in Sweden. *Gastrointest. Endosc.* *54*, 302–309.
48. Gatto, N.M., Frucht, H., Sundararajan, V., Jacobson, J.S., Grann, V.R., and Neugut, A.I. (2003). Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. *J. Natl. Cancer Inst.* *95*, 230–236.
49. Arora, N.K. (2009). Importance of patient-centered care in enhancing patient well-being: a cancer survivor's perspective. *Qual. Life Res.* *18*, 1–4.